150 related articles for article (PubMed ID: 9922079)
1. Thrombopoietic factors potentially useful in the treatment of acute leukemia.
Archimbaud E; Thomas X
Leuk Res; 1998 Dec; 22(12):1155-64. PubMed ID: 9922079
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of IL-3, SCF, IL-6, and IL-11 in treating thrombocytopenia.
Maslak P; Nimer SD
Semin Hematol; 1998 Jul; 35(3):253-60. PubMed ID: 9685171
[TBL] [Abstract][Full Text] [Related]
3. Thrombopoietic factors in chronic bone marrow failure states: the platelet problem revisited.
Kurzrock R
Clin Cancer Res; 2005 Feb; 11(4):1361-7. PubMed ID: 15746033
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic growth factors in cancer chemotherapy.
Crawford J; Foote M; Morstyn G
Cancer Chemother Biol Response Modif; 1999; 18():250-67. PubMed ID: 10800487
[TBL] [Abstract][Full Text] [Related]
5. Haematopoietic growth factors and their therapeutic use.
Wadhwa M; Thorpe R
Thromb Haemost; 2008 May; 99(5):863-73. PubMed ID: 18449415
[TBL] [Abstract][Full Text] [Related]
6. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma.
Vadhan-Raj S; Papadopoulos NE; Burgess MA; Linke KA; Patel SR; Hays C; Arcenas A; Plager C; Kudelka AP; Hittelman WN
J Clin Oncol; 1994 Apr; 12(4):715-24. PubMed ID: 8151315
[TBL] [Abstract][Full Text] [Related]
7. The role of platelet growth factors in cancer therapy.
Clarke K; Basser RL
Stem Cells; 1996; 14 Suppl 1():274-80. PubMed ID: 11012231
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
Bruserud O; Foss B; Petersen H
Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
[TBL] [Abstract][Full Text] [Related]
9. The use of hematopoietic growth factors in the treatment of acute leukemia.
Bradstock KF
Curr Pharm Des; 2002; 8(5):343-55. PubMed ID: 12069373
[TBL] [Abstract][Full Text] [Related]
10. Clinical use of hematopoietic growth factors.
Ganser A; Karthaus M
Curr Opin Oncol; 1996 Jul; 8(4):265-9. PubMed ID: 8869799
[TBL] [Abstract][Full Text] [Related]
11. Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors.
Siena S; Bregni M; Bonsi L; Sklenar I; Bagnara GP; Bonadonna G; Gianni AM
Exp Hematol; 1993 Nov; 21(12):1583-90. PubMed ID: 7691640
[TBL] [Abstract][Full Text] [Related]
12. Use of thrombopoietic growth factors in acute leukemia.
Kaushansky K
Leukemia; 2000 Mar; 14(3):505-8. PubMed ID: 10720151
[TBL] [Abstract][Full Text] [Related]
13. The new generation of recombinant human hematopoietic cytokines.
Hunt P; Foote M
Curr Opin Biotechnol; 1995 Dec; 6(6):692-7. PubMed ID: 8527842
[TBL] [Abstract][Full Text] [Related]
14. The cure of leukemia: a model for the role of humoral growth factors in cancer treatment.
Burke PJ
Semin Hematol; 1991 Jul; 28(3 Suppl 4):48-53. PubMed ID: 1723537
[No Abstract] [Full Text] [Related]
15. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L
J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia.
Drach D; Estrov Z; Zhao S; Drach J; Cork A; Collins D; Kantarjian H; Andreeff M
Leuk Lymphoma; 1994 Dec; 16(1-2):79-88. PubMed ID: 7535143
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer.
Jones SE; Khandelwal P; McIntyre K; Mennel R; Orr D; Kirby R; Agura E; Duncan L; Hyman W; Roque T; Regan D; Schuster M; Dimitrov N; Garrison L; Lange M
J Clin Oncol; 1999 Oct; 17(10):3025-32. PubMed ID: 10506596
[TBL] [Abstract][Full Text] [Related]
18. The impact of thrombopoietin on clinical practice.
Basser R
Curr Pharm Des; 2002; 8(5):369-77. PubMed ID: 12069375
[TBL] [Abstract][Full Text] [Related]
19. PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development.
Vadhan-Raj S
Stem Cells; 1994 May; 12(3):253-61. PubMed ID: 8075592
[TBL] [Abstract][Full Text] [Related]
20. Clinical applications of hematopoietic growth factors.
Vose JM; Armitage JO
J Clin Oncol; 1995 Apr; 13(4):1023-35. PubMed ID: 7535842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
